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A series of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives were syn-
thesized and tested for in vitro leishmanicidal activity against amastigotes of Leishmania amazonensis in axenical 
cultures and murine infected macrophages. Structure-activity relationships demonstrated the importance of a radi-
cal methoxy at position R3’, R4’ and R5’. (2E)-3-(3,4,5-trimethoxy-phenyl)-1-(3,6,7-trimethyl-1,4-dioxy-quinoxalin-
2-yl)-propenone was the most active. Cytotoxicity on macrophages revealed that this product was almost six times 
more active than toxic.
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Leishmaniasis is a tropical parasitosis caused by 
Trypanosomatidae of the Leishmania genus extended 
over Africa, Asia, Europe, North and South America, 
with an estimated 12 million people infected worldwide. 
Clinically, leishmaniasis occurs in visceral, cutaneous 
and mucocutaneous forms. Chemotherapy is restricted 
to pentavalent antimonials, amphotericin B and pentam-
idine, which require parenteral administration, are toxic, 
expensive and have restricted therapeutic spectrums in 
different clinical forms of leishmaniasis (Davis et al. 
2004). Recently, miltefosine has been shown to be active 
by oral treatment against Bolivian mucosal leishmania-
sis (Soto et al. 2007); however, this treatment is not very 
effective against other types of leishmaniasis (Yardley et 
al. 2005). In this context, the discovery of new active and 
promising compounds with anti-leishmanial potential 
remains essential for the control and prevention of leish-
maniasis. Quinoxaline derivatives have been reported 
to have anti-protozoal activity against malaria parasites 
(Rangisetty et al. 2001, Zarranz et al. 2005, Marin et al. 
2007) and also against promastigote forms of Leishma-
nia amazonensis and Leishmania infantum (Guillon et 
al. 2007). In our efforts to identify new anti-leishmanial 
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drug candidates, we describe herein the relationship 
between structure and anti-leishmanial activity of new 
quinoxaline 1,4-di-N-oxide derivatives on amastigotes 
of L. amazonensis (strain MHOM/BR/76/LTB-012). 
MAtERIAlS AnD MEthoDS
Chemicals and instruments - Alugram® SIL G/
UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & 
Co, KG, Postfach 101352. D-52313 Düren, Germany) 
was used for Thin Layer Chromatography and Silica gel 
60 (0.040-0.063 mm) for Column flash Chromatogra-
phy (Merck). All reagents and solvents were purchased 
from: Merck (Darmstadt, Germany), Scharlau (FERO-
SA, Barcelona, Spain), Panreac Química SA (Montcada 
i Reixac, Barcelona, Spain), Sigma-Aldrich Química 
SA, (Alcobendas, Madrid), Acros Organics (Janssen 
Pharmaceuticalaan 3a, 2440 Geel, België) and Lancaster 
(Bischheim-Strasbourg, France).
Compounds 2a-e, 3a-f, 4b and 4d (Table) were syn-
thesized according to Burguete et al. (2007). Melting 
points were determined with a Mettler FP82+FP80 ap-
paratus (Greifense, Switzerland) and have not been cor-
rected. The 1H NMR spectra were recorded on a Bruker 
400 UltrashieldTM (Bruker BioSpin GmbH, Rheinstetten, 
Germany), using TMS as the internal standard and with 
CDCl3 and DMSO-d6 as the solvents. 
Distribution coefficient (LogP) - LogP was calculated 
with the online software Pharma-algorithms (available 
from: http://pharma-algorithms.com/). LogP is a measure 
of a drug’s lipophilicity and an indication of its ability to 
cross cell membranes (Scherrer & Howard 1977). Drugs 
having values of p beyond 1 are classified as lipophilic, 
whereas those with partition coefficients smaller than 1 
are indicative of hydrophilic drugs. This can be calculated 
in silico or by using an HPLC method (Valkó 2004); the 
higher the value, the more lipophilic the drug.
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Activity of quinoxaline derivatives on axenic amas-
tigotes - Axenically grown amastigotes of L. amazonen-
sis (strain MHOM/BR/76/LTB-012) were maintained by 
weekly sub-passages in medium for axenically grown 
amastigotes (extensively described by Sereno & Lemesre 
1997a) and supplemented with 20% of foetal bovine se-
rum at 32ºC with 5% CO2 in 25 cm
2 tissue culture flasks. 
Cultures were initiated with 106 amastigotes/mL in 25 cm2 
tissue culture flasks with 5 mL of media. In order to deter-
mine the activity of the drugs, the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) micromethod 
was used as previously described by Sereno and Lemesre 
(1997b). Briefly, 100 µL of axenically grown amastigotes, 
from late LogPhase of growth, were seeded in 96-well flat 
bottom microtiter plates. The drugs, dissolved in dimeth-
ylsulfoxide (DMSO), were added at final concentrations 
ranging from 100 to 1 µg/mL. All experiments were per-
formed in triplicate. The final DMSO concentration was 
never greater than 0.1%. After 72 h of incubation, 10 µL of 
MTT (10 mg/mL) was added to each well and plates were 
further incubated for 4 h. The enzymatic reaction was then 
stopped with 100 µL of 50% isopropanol (v/v) -10% sodi-
um dodecyl sulphate (w/v) and incubated for an additional 
30 min, under agitation, at rt. Finally, the optical density 
was read at 590 nm with a 96-well scanner (Bio-Rad).
The percentage of growth inhibition of the parasite 
was calculated by the following formula:
(OD control - OD drugs) x 100 = % of inhibition                                   
OD control
The dose inhibiting 50% of the parasite growth (IC50) 
was calculated (Excel software).
Reference compounds were amphotericin B and glu-
conate antimoniate of meglumine (Glucantime).
Activity on infected macrophages - Macrophages 
were harvested from peritoneal cavities of 6-8 week-old 
female BALB/c mice in ice-cold M199 medium (supple-
mented with 10% foetal bovine serum), adapted from 
Sauvain et al. (1993). The cells were plated at 10
6
/mL 
on glass coverslips and incubated at 37°C under an at-
mosphere of 5% CO2 for 24 h. Non-adherent cells were 
removed by washing with pre-warmed M199 medium. 
Medium was then replaced by a suspension of amasti-
gotes, using an infection ratio of 3/1 amastigotes/mac-
rophages, for 2 h at 32°C in 5% CO2. Calls were then 
washed three times with pre-warmed M199 medium to 
remove free parasites. The drug to be tested, dissolved in 
DMSO, was then added and incubated for 48 h at 37°C in 
5% CO2. Cultures were subsequently fixed with absolute 
methanol, stained with Giemsa and examined by light 
microscopy. The number of intracellular amastigotes 
was determined by counting amastigotes in 300 mac-
rophages. All experiments were performed in triplicate. 
The infection rates (IR) were calculated according 
to Delorenzi et al. (2001) and Monzote et al. (2004). 
Then, the drug concentration able to reduce the IR in 
macrophages by 50%, IC50 (IR), was calculated using the 
PROBIT formula in Excel. 
 
Cytotoxicity on macrophages - Murine macrophages 
were treated with the drug and their viabilities were de-
termined by trypan blue dye exclusion. Living cells ex-
clude the dye, whereas dead cells take up the blue dye. 
Resident mouse macrophages adhering to 96-well plates 
TABLE
Antileishmanial activity on axenic amastigotes and infection rates of L. amazonensis and LogP calculated in silico  
(http://pharma-algorithms.com/) of the tested compounds
Drugs R6 R7 R3’ R4’ R5’ IC50 SI IC50 (IR) LogP
2a H H OCH3 OCH3 OCH3 4,9 ± 2.1   2,8 13,1 0.85
2b H OCH3 OCH3 OCH3 OCH3 65,6 ± 22.9   1,2 23,5 0.8
2c H Cl OCH3 OCH3 OCH3 37,0 ± 7.8   4,3 23,2 1.23
2d H F OCH3 OCH3 OCH3 2,7 ± 0.6   5,1 24,1 0.73
2e CH3 CH3 OCH3 OCH3 OCH3 4,1 ± 0.5 >5,7 17,7 1.67
3a H H                     O-CH2-O  H >100 NT - 1.49
3b H OCH3                                   O-CH2-O  H >100 NT - 1.44
3c H Cl                     O-CH2-O  H >100 NT - 1.87
3d H F                     O-CH2-O  H >100 NT - 1.37
3e CH3 CH3                                    O-CH2-O  H >100 NT - 2.31
3f H CH3                                    O-CH2-O  H >100 NT - 1.9
4b H OCH3                                   OCH3       OH H 5,3 ± 2.3 25,2 43,7 0.59
4d H F                     OCH3       OH H 6,7 ± 1.3 20,7 42,9 0.53
Amph.B      0.06 ± 0.01 73 0.6 -
IC50: concentration inhibiting 50% of the parasite growth, in µM; IR: infection rate; NT: not tested; SI: Selectivity Index (TD50/IC50).
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were incubated for 24 h at 37°C in 5% CO2. Drugs were 
then added and cells returned to culture for 48 h. Finally, 
macrophages were incubated with 0.4% trypan blue so-
lution and the viable cells were enumerated with a mi-
croscope. One hundred cells were counted for each con-
centration and the number of viable cells that excluded 
trypan blue was determined to calculate percentage of 
viability. The drug dose killing 50% of the macrophages 
(TD50) was then determined with the PROBIT formula of 
Excel software. Amphotericin B was used as a control.
RESultS AnD DISCuSSIon
Anti-leishmanial activities of the studied compounds 
are listed in Table.  Compounds 3a-f were inactive against 
axenic amastigotes with an IC50 > 100 µM. Compounds 
in series 2 and 4 presented the best anti-leishmanial activ-
ities, displaying IC50 ranging from 2.8 to 65.6 µM. We can 
therefore say that when the hydroxy and methoxy groups 
are substituted by a methylenedioxy group, the activ-
ity decreases dramatically. Moreover, product 2d with a 
fluorine atom in R7 was the most active against axenic 
amastigotes with an IC50 at around 3 µM.  The active com-
pounds (series: 2 and 4) were then evaluated on non-in-
fected macrophages to determinate their selectivity index. 
Products 4b and 4d were the most selective, followed by 
2e, 2d and 2c; products 2a and 2b were the least selec-
tive. Amphotericin B was also tested against non-infected 
macrophages and was shown to be around 70 times less 
cytotoxic on macrophages than on axenic amastigotes. 
In order to gain further insight into the ability of 
these drugs to cross cell membranes, LogP values 
were calculated by computational analysis with using 
the help of Pharma-algorithms (available from http://
pharma-algorithms.com) in silico. Compound 2e was 
shown to be the most lipophilic among the most ac-
tive compounds. Interestingly, apart from 2e, the active 
compounds against axenic amastigotes had LogP values 
< 1.25, while inactive drugs showed LogP values > 1.25. 
These results are in agreement with previously pub-
lished results by Valderama et al. (2005) showing that 
the lipophilicity of leishmanicidal quinones is correlated 
with their leishmanicidal activity. Compounds 4b and 
4d, with a hydroxyl group in the structure, were less ac-
tive (IC50 (IR) > 40 µM) against L. amazonensis infected 
macrophages than compounds in group 2, with three 
methoxy groups. Interestingly, 2b, 2c and 2d have simi-
lar IC50 (IR) (> 20µM), while 2a and 2e have the low-
est IC50 (IR) (around 13.1 µM and 17.7 µM respectively); 
with compound 2e showing less cytotoxicity than 2a.
Thus, our results suggest that compound 2e, (2E)-3-
(3,4,5-trimethoxy-phenyl)-1-(3,6,7-trimethyl-1,4-dioxy-
quinoxalin-2-yl)-propenone, should be considered for 
further in vivo studies against Leishmania parasites. 
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